- Eli Lilly received full FDA approval for an all-oral regimen containing its estrogen receptor antagonist Inluriyo and kinase inhibitor Verzenio as a late-line breast cancer treatment.
- Lilly Oncology president Jake Van Naarden said the combination's longer progression-free survival leads him to expect most patients to choose it over oral SERD monotherapy.
- The approval intensifies competition in oral SERDs, where Lilly positions a dual-agent regimen against single-agent alternatives.
Quotes
“With longer progression-free survival, Jake Van Naarden, president of Lilly Oncology, told Fierce he expects most patients to choose the combination over oral SERD monotherapy.”
Sources
- <a href="https://www.fiercepharma.com/pharma/eli-lilly-escalates-oral-serd-battle-fda-approval-inluriyo-verzenio-combo" hreflang="en">Eli Lilly escalates oral SERD battle with FDA approval for Inluriyo, Verzenio combo</a>FiercePharma
- Lilly wins full FDA approval for Inluriyo combo in breast cancerSeekingalpha